MS is a chronic disease that affects the nervous system. Nerves are coated in a protective covering called myelin, which also speeds up the transmission of nerve signals. People with MS experience progressive deterioration of myelin.
Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With MS Treated With Ampyra (Dalfampridine-ER): STUDY
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-Ampyra (fampridine) treatment of patients with MS: STUDY
Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY
Effect of Ampyra (Fampridine-PR / prolonged released 4-aminopyridine) on the manual functions of patients with MS: STUDY
Withdrawal/reinitiation study expands on known walking speed benefits of approved MS therapy
In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the International Journal of MS Care.